Verona Pharma (VRNA)

• Market cap: $5.38B
• 1 day: -1.57%
• 5 days: 12.43%
• 1 month: 13.51%
• 3 months: 25.91%
• 6 months: 110.79%
• Year to date: 49.52%
• 1 year: 366.47%
• 5 years: 1,599.76%
• 10 years: 433.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Employees: 209

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

342% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 12

325% more call options, than puts

Call options by funds: $71.2M | Put options by funds: $16.7M

109% more funds holding in top 10

Funds holding in top 10: 11 [Q3] → 23 (+12) [Q4]

63% more capital invested

Capital invested by funds: $1.95B [Q3] → $3.19B (+$1.24B) [Q4]

27% more funds holding

Funds holding: 150 [Q3] → 191 (+41) [Q4]

0.07% more ownership

Funds ownership: 10.41% [Q3] → 10.48% (+0.07%) [Q4]

5% less repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 60

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $72 0% upside
• Avg. target: $88 22% upside
• High target: $107 48% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Tiago Fauth 32% 1-year accuracy 9 / 28 met price target	48% upside $107	Overweight Maintained	30 Apr 2025
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 328 met price target	18% upside $85	Buy Maintained	30 Apr 2025
Canaccord Genuity Edward Nash 65% 1-year accuracy 13 / 20 met price target	0% downside $72	Buy Maintained	12 Feb 2025